XML 13 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue:        
Total revenue $ 1,076 $ 123 $ 5,163 $ 26,486
Operating costs and expenses:        
Cost of goods sold $ (58) $ (75) $ 278 $ 21,407
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 1,209 $ 19,974 $ 16,249 $ 88,824
Selling, general and administrative 5,295 9,362 20,459 40,984
Restructuring charge 41 18,554 560 18,554
Total operating costs and expenses 6,487 47,815 37,546 169,769
Loss from operations (5,411) (47,692) (32,383) (143,283)
Interest and other, net        
Interest expense (2,083) (2,069) (6,346) (6,029)
Loss on debt extinguishments (6,583) 0 (6,583) 0
Interest income and other income (expenses), net 931 1,472 1,628 4,608
Total interest and other, net (7,735) (597) (11,301) (1,421)
Loss from continuing operations before income taxes (13,146) (48,289) (43,684) (144,704)
Provision for (benefit from) income taxes 0 3 (90) (271)
Loss from continuing operations (13,146) (48,292) (43,594) (144,433)
Income from discontinued operations, net of tax 213,782 31,208 241,266 78,872
Net income (loss) $ 200,636 $ (17,084) $ 197,672 $ (65,561)
Loss from continuing operations per share - basic $ (3.25) $ (12.01) $ (10.79) $ (36.19)
Loss from continuing operations per share - diluted (3.25) (12.01) (10.79) (36.19)
Income from discontinued operations per share - basic 52.86 7.76 59.69 19.76
Income from discontinued operations per share - diluted 52.86 7.76 59.69 19.76
Net income (loss) per share - basic 49.61 (4.25) 48.9 (16.43)
Net income (loss) per share - diluted $ 49.61 $ (4.25) $ 48.9 $ (16.43)
Weighted average number of common shares used to calculate net income (loss) per share:        
Basic 4,044 4,021 4,042 3,991
Diluted 4,044 4,021 4,042 3,991
Development and Other Revenue [Member]        
Revenue:        
Total revenue $ 119 $ 385 $ 396 $ 1,532
Drug Product Revenue, Net [Member]        
Revenue:        
Total revenue $ 957 $ (262) $ 4,767 $ 24,954